New York, May 28, 2026, 14:02 EDT
MapLight Therapeutics shares slipped Thursday. New Wall Street research coverage still pointed to the company’s clinical-trial results coming in mid-August, which investors say is the next key test for a stock that’s traded far above its IPO level.
The stock traded at $29.17, down 1.3%. The SPDR S&P Biotech ETF added 0.8%, while iShares Nasdaq Biotechnology ETF climbed 1.1%. MapLight carried a market cap close to $1.32 billion. Shares changed hands between $28.72 and $30.33 during the session.
Nasdaq’s regular trading session was underway. U.S. stock-market hours are listed by Nasdaq as 9:30 a.m. to 4 p.m. Eastern, and Memorial Day, May 25, is posted as the 2026 market holiday, not Thursday.
Why it matters: MapLight is a clinical-stage biotech. Shares mostly trade on trial results, not revenue. The company doesn’t have a marketed product. Investors are waiting for Phase 2 data from two ongoing programs. Both are expected by mid-August. These studies are in humans and look at safety and potential benefits.
UBS analyst Ashwani Verma picked up coverage Wednesday with a Buy and a $48 target, citing the August data readout as a “major near-term catalyst.” Verma said risk/reward was “meaningfully favorable” ahead of the schizophrenia results. TipRanks
H.C. Wainwright & Co. posted a $45 target on Thursday, the newest update on Benzinga’s analyst tracker. The tracker showed a consensus price target of $36.89 from 10 analysts. The range was $28 on the low end, $48 at the high.
MapLight finished enrolling 307 people in ZEPHYR, its Phase 2 study of ML-007C-MA in schizophrenia, earlier this month. The company expects to have topline data by mid-August. Topline results give an early look at whether the trial met its main endpoints.
MapLight CEO Chris Kroeger told investors in a May 14 update the company was at an “important inflection point” as it looks for data from both ZEPHYR and a second Phase 2 study, IRIS. MapLight finished March with $395.2 million in cash, cash equivalents and investments, which it said should cover operations into 2027. The first-quarter net loss increased to $60.7 million, up from $22.3 million a year ago. SEC
IRIS has finished the last patient visit for ML-004 in autism spectrum disorder, with results due by mid-August. Kroeger earlier in May said “robust enrollment” in ZEPHYR showed there’s still a “critical unmet need” for new schizophrenia options. Maplight Therapeutics
MapLight’s main drug works in the muscarinic space, targeting the muscarinic receptors in nerve signals. Bristol Myers Squibb’s Cobenfy is the best-known name in this group after it won FDA approval in 2024 for schizophrenia. Cobenfy was the first antipsychotic here approved for hitting cholinergic instead of dopamine receptors.
MapLight also has a longer-term Alzheimer’s disease psychosis trial. In January, the company said the FDA gave Fast Track status to ML-007C-MA for hallucinations and delusions in Alzheimer’s disease psychosis. The Fast Track program is aimed at serious diseases with unmet treatment need.
The risks go both ways for MapLight. Shares could fall sharply if schizophrenia or autism results disappoint, if safety issues crop up, or if there’s another delay. The company’s value is mostly tied to clinical milestones rather than revenue. MapLight has cautioned that earlier data might not match up with later trial results, and regulatory approval timing is still up in the air.
MapLight stock trades about 72% higher than its $17 IPO price. The company listed in October. At the IPO, Reuters said Novo Holdings backed MapLight and that it was working on drugs for CNS disorders like schizophrenia, Alzheimer’s disease psychosis, autism spectrum disorder, and Parkinson’s disease.
